GET DAILY SIGNALSFennec Pharmaceuticals (FENC) Posts Strong Q3 Results with +56% Sales Growth
Key Takeaways
- Fennec reported third-quarter 2026 net product sales of $19.4 million, up roughly 56% from $12.5 million in the same period a year earlier.
- GAAP earnings per share came in at $0.12, beating the consensus estimate of $0.09 by $0.02 and swinging from a $0.02 loss a year ago.
- Revenue of $19.4 million topped consensus expectations by about $0.53 million, extending a streak of strong commercial momentum for PEDMARK.
- Adjusted EBITDA reached a record $5.8 million, or 30% of net product sales, up from $2.0 million a year earlier.
- The company generated nearly $7 million in cash from operations during the quarter, ending with $48.7 million in cash and no debt.
Why These Results Matter
Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on PEDMARK, a treatment designed to reduce the risk of platinum-induced ototoxicity in cancer patients receiving cisplatin-based chemotherapy. This quarter offers a clear read on whether the expanded commercial organization can convert demand into sustained, profitable growth. After a strategic sales-force expansion earlier in 2026, I am watching closely to see whether new and existing accounts continue driving product sales higher while operating leverage improves. With PEDMARK holding orphan drug exclusivity and growing clinical data support, the third-quarter results provide a key benchmark for the company's transition toward durable profitability.
The Reported Numbers
Fennec Pharmaceuticals reported third-quarter 2026 net product sales of $19.4 million, a year-over-year increase of approximately 56% from $12.5 million. Total revenue of $19.4 million exceeded consensus estimates by roughly $0.53 million. GAAP net income was $4.64 million, and diluted earnings per share reached $0.12, beating the consensus estimate of $0.09 and improving sharply from a net loss of $0.64 million, or $0.02 per share, in the prior-year quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company reported record adjusted EBITDA of $5.8 million, equivalent to 30% of net product sales, up from $2.0 million, or 16% of net product sales, a year earlier. Management highlighted significant operating leverage, with EBITDA growth of roughly $3 million on about $2.3 million of incremental revenue. Patient enrollments in the Fennec HEARS support program rose 23% sequentially, and completed infusions increased 58%, signaling robust underlying demand heading into the fourth quarter.
Market Reaction and Investor Sentiment
Investor sentiment heading into the report reflected growing confidence in Fennec's commercial execution, and the results reinforced that narrative. The company beat both revenue and earnings expectations, reported a record adjusted EBITDA margin, and generated its highest quarterly operating cash flow to date. Management also pointed to strong visibility into the fourth quarter, citing the largest-ever carryover of planned infusions and vials from the third quarter alongside a robust October. These factors suggest the market is likely to view the quarter favorably, with the key debate shifting toward the sustainability of margin expansion and the pace of new account additions rather than near-term demand.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should focus on whether Fennec can sustain its double-digit commercial growth while continuing to expand adjusted EBITDA margins. Management reiterated that fourth-quarter 2026 cash operating expenses are expected to be the lowest of the year, which could support further profitability gains. The company also cited strong carryover of planned infusions and vials from the third quarter, suggesting momentum may persist into the next reporting period.
Several catalysts are worth monitoring. New clinical data, including interim results from investigator-initiated studies in adult and metastatic patient populations, could broaden the addressable market beyond the current pediatric and adolescent indications. Additional formulary wins at academic centers and expanded use in community oncology practices may also accelerate adoption. On the cost side, investors should track whether the expanded commercial investment continues to translate into productivity gains rather than elevated expenses.
Finally, balance-sheet strength remains a supportive factor. With $48.7 million in cash and no debt, Fennec has financial flexibility to fund further growth initiatives and evidence generation. The central question is execution: whether the company can keep converting rising demand into sustainable, cash-generating profitability.
Using Tickeron Tools in My Research
I often turn to Tickeron’s AI tools when analyzing earnings reports like this one. The AI Screener helps me quickly compare fundamentals and technical signals across similar names, while the AI Trend Prediction Engine gives me a sense of potential follow-through moves. These resources fit naturally into my routine for spotting patterns and validating ideas without replacing my own judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FENC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
FENC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 39 cases where FENC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for FENC just turned positive on November 09, 2026. Looking at past instances where FENC's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.
Following a +15.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where FENC advanced for three days, in 203 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FENC as a result. In 93 of 113 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
FENC moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FENC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for FENC entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.105) is normal, around the industry mean (3.498). FENC has a moderately low P/E Ratio (-81.750) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.100) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.963) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. FENC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FENC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic products based on cell adhesion
Industry Biotechnology
Advertisement